

28.06.18

ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000

RESULTS OF EXTRAORDINARY GENERAL MEETING

Admedus Limited (ASX:AHZ) (the **Company**) confirms that all resolutions put to the Extraordinary General Meeting held today have been passed.

Details of the resolutions and the proxy and poll voting results received in respect of each resolution are set out in the attached voting summary in accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth).



Resolution details		
Resolution	Resolution Type	
1 APPROVAL TO ISSUE SHARES TO MR MATHEW RATTY	Ordinary	
2 APPROVAL TO ISSUE SHARES TO MY WAYNE PATERSON	Ordinary	
3 APPROVAL TO ISSUE SHARES TO MR JOHN SEABERG	Ordinary	
4 APPROVAL TO ISSUE SHARES TO MR SIMON BUCKINGHAM	Ordinary	
5 RATIFICATION OF PLACEMENT	Ordinary	

Instructions given to validly appointed proxies (as at proxy close)			
For	Against	Proxy's Discretion	Abstain
62,490,336	6,585,983	3,556,417	689,616
86.03%	9.07%	4.90%	
64,583,338	4,584,124	3,556,417	598,473
88.81%	6.30%	4.89%	
62,799,570	4,685,690	4,143,584	1,693,508
87.67%	6.54%	5.78%	
64,405,729	4,685,690	3,558,417	672,516
88.65%	6.45%	4.90%	
38,137,079	2,381,405	1,170,756	2,803,845
91.48%	5.71%	2.81%	

Resolution Result	
Carried / Not Carried	
Carried on a show of hands	
Carried on a show of hands	
Carried on a show of hands	
Carried on a show of hands	
Carried on a show of hands	

ENDS

^{*} Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.



About Admedus Limited

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: <u>www.admedus.com</u>

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com

Admedus Limited ABN 35 088 221 078

Registered Office Level 9 301 Coronation Drive Milton QLD 4064 Customer Service T 1300 550 310 F 1300 880 398

F: +61 8 9266 0199

International T: +61 8 9266 0100 E: info@admedus.com W: www.admedus.com

Brisbane • Minneapolis
Zurich • Singapore